Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1991 Oct;155(4):415–416.

Cisplatin therapy-associated recurrent toxic shock syndrome.

A C Berman 1, L R Boly 1
PMCID: PMC1003032  PMID: 1771888

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergdoll M. S. Regulation and control of toxic shock syndrome toxin 1: overview. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S142–S144. [PubMed] [Google Scholar]
  2. Buckley J. E., Clark V. L., Meyer T. J., Pearlman N. W. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med. 1984 Dec;144(12):2347–2348. [PubMed] [Google Scholar]
  3. Chesney P. J. Clinical aspects and spectrum of illness of toxic shock syndrome: overview. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S1–S7. [PubMed] [Google Scholar]
  4. Chow A. W., Bartlett K. H. Sequential assessment of vaginal microflora in healthy women randomly assigned to tampon or napkin use. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S68–S74. doi: 10.1093/clinids/11.supplement_1.s68. [DOI] [PubMed] [Google Scholar]
  5. Kass E. H. Magnesium and the pathogenesis of toxic shock syndrome. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S167–S175. doi: 10.1093/clinids/11.supplement_1.s167. [DOI] [PubMed] [Google Scholar]
  6. Kass E. H. Magnesium, Staphylococcus aureus and toxic shock syndrome. Magnesium. 1988;7(5-6):315–319. [PubMed] [Google Scholar]
  7. Lam M., Adelstein D. J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis. 1986 Sep;8(3):164–169. doi: 10.1016/s0272-6386(86)80020-8. [DOI] [PubMed] [Google Scholar]
  8. Pun K. K., Ho P. W. Subclinical hyponatremia, hyperkalemia and hypomagnesemia in patients with poorly controlled diabetes mellitus. Diabetes Res Clin Pract. 1989 Sep 18;7(3):163–167. doi: 10.1016/0168-8227(89)90001-6. [DOI] [PubMed] [Google Scholar]
  9. Reeves M. W. Effect of trace metals on the synthesis of toxic shock syndrome toxin 1. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S145–S150. doi: 10.1093/clinids/11.supplement_1.s145. [DOI] [PubMed] [Google Scholar]
  10. Reingold A. L., Hargrett N. T., Shands K. N., Dan B. B., Schmid G. P., Strickland B. Y., Broome C. V. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med. 1982 Jun;96(6 Pt 2):875–880. doi: 10.7326/0003-4819-96-6-875. [DOI] [PubMed] [Google Scholar]
  11. Schilsky R. L., Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun;90(6):929–931. doi: 10.7326/0003-4819-90-6-929. [DOI] [PubMed] [Google Scholar]
  12. Schlievert P. M. Role of toxic shock syndrome toxin 1 in toxic shock syndrome: overview. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S107–S109. doi: 10.1093/clinids/11.supplement_1.s107. [DOI] [PubMed] [Google Scholar]
  13. Vogelzang N. J., Torkelson J. L., Kennedy B. J. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985 Dec 15;56(12):2765–2770. doi: 10.1002/1097-0142(19851215)56:12<2765::aid-cncr2820561208>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES